From oral IL-23 blockade in UC to sex-specific FIT thresholds and a swallowable Barrett’s test, these are 7 trials from ACG 2026 clinicians should know.
News|Articles|October 5, 2026
5 Hepatology Headlines You Missed in September 2026
Author(s)Alex Hillenbrand
Fact checked by: Chelsie Derman
Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.
Advertisement
Advertisement
Related to this article
A real-world ACG 2026 study found 23.4% of patients with PBC on elafibranor reached ALP of 120 U/L or lower, versus 14.6% on obeticholic acid.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.
Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.
Long-term extension data show iptacopan held a −3.49 mL/min/1.73 m² per year eGFR slope over 48 months, with benefit emerging after patients switched from placebo.
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
Advertisement
Advertisement